Skip to main content

Table 2 Changes in medication treatment 1 year after pharmacist consultation:

From: The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study

Variable Pharmacist consultation group (N = 740) Control group (N = 1476) p-value
Total medications at baseline N (Mean; CI) 11.4 ± 2.4 9.9 ± 2.4  < 0.001
Medications stopped N (Mean; SD) 1.5 ± 1.1 0.7 ± 0.9  < 0.001
Medications started N (Mean; SD) 1.3 ± 0.8 0.4 ± 0.8  < 0.001
Proportion of patients that stopped at least one medication, N (%) 610 (82.4) 712 (48.2)  < 0.001
Proportion of patients that started at least one medication, N (%) 483 (65.2) 373 (25.2)  < 0.001
Medications adherence before % (Mean; SD) 79.3 ± 16.3 83.7 ± 14.3 0.014
Medications adherence after % (Mean; SD) 81.1 ± 15.1 88.4 ± 11.8  < 0.001
Difference in adherence % (Mean; SD) 1.6 ± 13.6 4.7 ± 14.2 0.036
Patients on anxiolytics N (%) 136 (18.4) 377 (25.5)  < 0.001
Patients who stopped anxiolytics (BNZ) N (% anxiolytics users) 80 (58.8) 165 (43.8) 0.029
Patients who started anxiolytics (BNZ) N (%) 30 (22) 142 (37.7)  < 0.001
Patients on chronic opioids 341 pts N (% opioids users) 72 (9.7) 269 (18.2)  < 0.001
Patients who stopped opioids N (%) 36 (50.0) 85 (31.6)  < 0.001
Patients who started opioids N (%) 22 (30.6) 114 (42.4) 0.07
Diabetic patients with sulfonylureas N (%) 112 (20.4) 252 (23.1)  < 0.001
Diabetic patients who stopped sulfonylureas, N (%) 12 (10.7) 12 (3.6)  < 0.001
Diabetic patients who started Sulfonylureas, N (%) 10 (8.9) 35 (13.8)  < 0.001
Diabetic patients with GLP1 N (%) 98 (17.9) 160 (14.6) 0.06
Diabetic patients who stopped GLP1, N (%) 2 (2.0) 15 (9.4)  < 0.001
Diabetic patients who started GLP1, N (%) 16 (16.4) 18 (11.2) 0.031